Patent US2326439A successfully refreshed from Google Patents.
Patent US5591140A successfully refreshed from Google Patents.
US5591140A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents
Assignee: Cordis Corp
•
Filing: 1995-04-06
•
Granted: 1997-01-07
•
Expires: 2015-04-06
Abstract
Abstract Polymeric surfaces of medical devices or components of medical devices are provided that have enhanced biocompatibility properties. The polymeric surface presents an anti-thrombogenic, fibrinolytic or thrombolytic interface with body fluids such as blood during implantation or medical procedures. The biocompatibility enhancing agent is secured to the polymeric substrate by a spacer molecule which is covalently bound to the polymeric substrate which had been subjected to radiofrequency plasma treatment with a water vapor medium.
Inventors
- 👤 Pallassana V. Narayanan
- 👤 Kimberly D. Stanley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:11
CPC Classifications
B; B29; B29C; B29C59/00; B29C59/14; B29C59/142; A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0029; Y; Y10; Y10S; Y10S522/00; Y10S522/915; Y10S525/00; Y10S525/937; Y10S530/00; Y10S530/81; Y10S530/812; Y10S530/815; Y10S530/816
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
221 words
A method for enhancing the biocompatibility of medical device polymeric surfaces, comprising the steps of: positioning a polymeric surface within a radiofrequency plasma discharge environment; inserting water vapor into said radiofrequency plasma discharge environment to provide a water vapor plasma medium having in excess of about 90 volume percent water vapor, based upon the total volume of the plasma medium; subjecting said water vapor plasma medium within the environment to a radiofrequency electric field in order to form reactive species from said water vapor gas within the environment and to have the reactive species react with the polymeric surface to form a modified polymeric surface having reactive sites; treating said modified polymeric surface with a spacer component having amine groups, said treating step being in the presence of a coupling agent, whereby covalent linkages are formed between the spacer component amine groups and the reactive sites of the modified polymeric surface; and contacting an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality and biologically active properties with said spacer component-treated modified polymeric surface, whereby said medical device polymeric surface exhibits biocompatibility improvements over said polymeric surface which is not treated according to the method, and whereby said biocompatible medical device polymeric surface anti-thrombogenic, fibrinolytic or thrombolytic agent is resistant to extraction under in vivo conditions while retaining its biologically active properties.
Claim 2
Independent Claim
221 words
A method for enhancing the biocompatibility of medical device polymeric surfaces, comprising the steps of: positioning a polymeric surface within a radiofrequency plasma discharge environment; inserting water vapor into said radiofrequency plasma discharge environment to provide a water vapor plasma medium having in excess of about 90 volume percent water vapor, based upon the total volume of the plasma medium; subjecting said water vapor plasma medium within the environment to a radiofrequency electric field in order to form reactive species from said water vapor gas within the environment and to have the reactive species react with the polymeric surface to form a modified polymeric surface having reactive sites; treating said modified polymeric surface with a spacer component having amine groups, said treating step being in the presence of a coupling agent, whereby covalent linkages are formed between the spacer component amine groups and the reactive sites of the modified polymeric surface; and contacting an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality and biologically active properties with said spacer component-treated modified polymeric surface, whereby said medical device polymeric surface exhibits biocompatibility improvements over said polymeric surface which is not treated according to the method, and whereby said biocompatible medical device polymeric surface anti-thrombogenic, fibrinolytic or thrombolytic agent is resistant to extraction under in vivo conditions while retaining its biologically active properties.
Claim 3
Dependent Claim
27 words
The method in accordance with claim 1, wherein said plasma medium includes approximately 100 volume percent water vapor, based upon the total volume of the plasma medium.
Claim 4
Dependent Claim
32 words
The method in accordance with claim 1, wherein said treating step utilizes a spacer component which is an amine selected from the group consisting of primary amines, secondary amines, and combinations thereof.
Claim 5
Dependent Claim
24 words
The method in accordance with claim 1, wherein said reactive sites formed by said subjecting step include carboxyl groups, hydroxyl groups or combinations thereof.
Claim 6
Dependent Claim
20 words
The method in accordance with claim 1, wherein said reactive sites formed by said subjecting step include carboxyl groups thereof.
Claim 7
Dependent Claim
22 words
The method in accordance with claim 1, wherein said contacting step contacts said spacer component-treated modified polymeric surface with a heparinous component.
Claim 8
Dependent Claim
21 words
The method in accordance with claim 1, wherein said plasma discharge environment is evacuated prior to said water vapor inserting step.
Claim 9
Dependent Claim
116 words
A medical device having a biocompatible polymeric surface, wherein said biocompatible polymeric surface comprises a surface which has been modified by subjecting the polymeric surface to radiofrequency discharge treatment within a water vapor plasma medium having in excess of about 90 volume percent water vapor, based upon the total volume of plasma medium, followed by treatment with a coupling agent and a spacer component having amine groups forming covalent linkages with the polymeric surface which had been subjected to radiofrequency discharge treatment with said plasma medium, and then by treatment with an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality contacting and covalently bonding with the spacer component-treated polymeric surface to provide the biocompatible polymeric surface.
Claim 10
Dependent Claim
116 words
A medical device having a biocompatible polymeric surface, wherein said biocompatible polymeric surface comprises a surface which has been modified by subjecting the polymeric surface to radiofrequency discharge treatment within a water vapor plasma medium having in excess of about 90 volume percent water vapor, based upon the total volume of plasma medium, followed by treatment with a coupling agent and a spacer component having amine groups forming covalent linkages with the polymeric surface which had been subjected to radiofrequency discharge treatment with said plasma medium, and then by treatment with an anti-thrombogenic, fibrinolytic or thrombolytic agent having acid functionality contacting and covalently bonding with the spacer component-treated polymeric surface to provide the biocompatible polymeric surface.
Claim 11
Dependent Claim
47 words
The medical device in accordance with claim 8, wherein said covalent linkages between the modified polymeric surface and the spacer component are between carboxyl or hydroxyl groups formed by the radiofrequency discharge treatment on the polymeric surface and primary or secondary amine groups of the spacer component.
Claim 12
Dependent Claim
41 words
The medical device in accordance with claim 9, wherein a covalent linkage is present between one or more of said primary or secondary amine groups of spacer component molecules and the acid functionality groups of the anti-thrombogenic, fibrinolytic or thrombolytic agent.
Claim 13
Dependent Claim
31 words
The medical device in accordance with claim 8, wherein said water vapor plasma medium has approximately 100 volume percent water vapor gas, based on the total volume of the plasma medium.
Claim 14
Dependent Claim
16 words
The medical device in accordance with claim 8, wherein said polymeric surface is a polyurethane surface.
Claim 15
Dependent Claim
19 words
The medical device in accordance with claim 8, wherein said polymeric surface is a polyurethane or a polyurethane copolymer.
Claim 16
Dependent Claim
24 words
The medical device in accordance with claim 8, wherein the medical device is a component of a catheter, cannula, medical device balloon, or guidewire.
References Cited (Backward Citations)
US3600122A
Cited
US4116898A
Cited
US4265927A
Cited
US4131691A
Cited
US4261806A
Cited
US4266999A
Cited
US4326532A
Cited
US4678671A
Cited
US4613517A
Cited
US4692347A
Cited
US4656083A
Cited
US4632842A
Cited
US4919659A
Cited
US5338770A
Cited
US4948628A
Cited
US4846101A
Cited
US5244629A
Cited
US5234723A
Cited
US5132108A
Cited
US5244654A
Cited
US5409696A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-07 | 2000-07-08 | 2001-01-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-07 | 2004-07-08 | 2005-01-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-07 | 2008-07-08 | 2009-01-07 | $7700.00 | Window Closed / Lapsed |